NCT05754684View on ClinicalTrials.gov

Quadruple Immunotherapy for Neuroblastoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Neuroblastoma Recurrent
Interventions
BIOLOGICAL

Natural killer cell

Natural killer cells isolated from HLA-haploidentical relative donor

DRUG

Dinutuximab beta

Dinutuximab beta iv for 5 days

DRUG

Interleukin-2

Interleukin-2 sc alternate day for 6 doses

DRUG

Granulocyte-Macrophage Colony-Stimulating Factor

Granulocyte-macrophage colony-stimulating factor sc daily till ANC \>2,000/mm3

DRUG

Spironolactone

Spironolactone po three time daily

DRUG

Naxitamab

Naxitamab iv for 4 days (as alternative for dinutuximab)

Trial Locations (1)

Unknown

RECRUITING

Hong Kong Children's Hospital, Hong Kong

All Listed Sponsors
collaborator

The University of Hong Kong

OTHER

lead

Hong Kong Children's Hospital

OTHER